Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
2.
Br J Ophthalmol ; 90(3): 307-9, 2006 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-16488951

RESUMEN

BACKGROUND/AIMS: The literature on refractive change in thyroid eye disease (TED) is limited. This study documents the refractive change in patients with TED undergoing orbital decompression. The authors propose possible mechanisms for their acquired refractive error. METHODS: This is a retrospective observational case study of five patients with progressive TED. Their detailed eye examinations including refractive state preoperatively and postoperatively are presented. RESULTS: An acquired hypermetropic shift with active TED before orbital decompression of up to 3.75 D spherical equivalent refraction (SER) is reported in one patient. Post-orbital decompression, an induced myopic shift of between 1.00-2.50 D SER for all patients is observed, noted to range from 1 day following surgery to up to 9 months, dependent on the availability of data. Axial length increased in two cases corresponding to postoperative myopic shift. Magnetic resonance imaging findings of one patient demonstrate flattening of the posterior pole as a cause of the acquired preoperative hypermetropia. CONCLUSIONS: TED has a significant effect on the refractive state of patients. The proposed mechanism of acquired hypermetropia relates to increased volume of orbital contents with flattening of the posterior globe. This is reversed with successful orbital decompression. Documentation of refractive error in all cases of progressive TED is recommended. Progressive acquired hypermetropia may be suggestive of TED activity.


Asunto(s)
Oftalmopatía de Graves/complicaciones , Errores de Refracción/etiología , Adulto , Descompresión Quirúrgica , Progresión de la Enfermedad , Femenino , Oftalmopatía de Graves/fisiopatología , Oftalmopatía de Graves/cirugía , Humanos , Hiperopía/etiología , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Miopía/etiología , Refracción Ocular , Estudios Retrospectivos
3.
Am Surg ; 62(1): 81-8, 1996 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-8540654

RESUMEN

Approximately 20 per cent of melanomas greater than 0.76 mm in thickness will metastasize to the regional lymph nodes if treated with wide local excision alone (WLE). Elective lymph node dissection (ELND) is associated with significant morbidity, which includes lymphedema, wound complications, and paresthesias of the extremity. An alternative operative approach uses selective lymphadenectomy with the identification of the sentinel node, defined as the first node in the lymphatic basin that drains the primary cutaneous site. This study consisted of 132 patients with melanomas greater than 0.76 mm. One hundred nine patients (83%) had histologic negative sentinel nodes, and 23 patients (17%) had one or more sentinel nodes positive for disease. In patients with metastatic disease, 30/35 (86%) sentinel nodes were positive, and 25/357 (7%) nonsentinel nodes were positive (P < 0.001). In 18 patients (78%) of the 23 patients with metastatic disease, the sentinel node was the only node positive, strongly suggesting that there is an orderly progression of metastases. Two patients developed metastatic nodal disease after removal of a negative sentinel node (false negative rate = 1.5). The mean follow-up was 1 year. Sentinel node histology reflects the histology of the remainder of the nodes in the lymphatic basin and "skip" metastases, defined as a negative sentinel node but positive nodes higher in the regional chain positive for metastases or an axillary recurrence after a negative sentinel node biopsy, are rare for malignant melanoma. Harvesting the sentinel node in patients with intermediate or greater thickness melanoma will, therefore, identify a subset of patients with metastatic disease who have the most to benefit from a complete node dissection. This surgical approach allows for complete pathological staging and therapeutic management of patients while significantly reducing expense and overall morbidity.


Asunto(s)
Melanoma/diagnóstico , Melanoma/secundario , Neoplasias Cutáneas/patología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Antígenos de Neoplasias/análisis , Distribución Binomial , Femenino , Estudios de Seguimiento , Humanos , Periodo Intraoperatorio , Escisión del Ganglio Linfático , Metástasis Linfática , Masculino , Melanoma/cirugía , Antígenos Específicos del Melanoma , Persona de Mediana Edad , Monofenol Monooxigenasa/genética , Proteínas de Neoplasias/análisis , Reacción en Cadena de la Polimerasa , Valor Predictivo de las Pruebas , ARN Mensajero/análisis , Colorantes de Rosanilina , Proteínas S100/análisis , Neoplasias Cutáneas/cirugía , Coloración y Etiquetado/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA